Takata M - Search Results

1

Loss of expression of the metastasis suppressor gene KiSS1 during melanoma progression and its association with LOH of chromosome 6q16.3-q23.

Shirasaki F, Takata M, Hatta N, Takehara K. Shirasaki F, et al. Among authors: takata m. Cancer Res. 2001 Oct 15;61(20):7422-5. Cancer Res. 2001. PMID: 11606374

2

Tumour cells of extramammary Paget's disease do not show either p53 mutation or allelic loss at several selected loci implicated in other cancers.

Takata M, Hatta N, Takehara K. Takata M, et al. Br J Cancer. 1997;76(7):904-8. doi: 10.1038/bjc.1997.482. Br J Cancer. 1997. PMID: 9328150 Free PMC article.

3

Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression.

Morita R, Fujimoto A, Hatta N, Takehara K, Takata M. Morita R, et al. Among authors: takata m. J Invest Dermatol. 1998 Dec;111(6):919-24. doi: 10.1046/j.1523-1747.1998.00458.x. J Invest Dermatol. 1998. PMID: 9856796 Free article.

4

p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma.

Fujimoto A, Morita R, Hatta N, Takehara K, Takata M. Fujimoto A, et al. Among authors: takata m. Oncogene. 1999 Apr 15;18(15):2527-32. doi: 10.1038/sj.onc.1202803. Oncogene. 1999. PMID: 10229204

5

Mapping of occult melanoma micrometastases in the inguinal lymph node basin by immunohistochemistry and RT-PCR.

Hatta N, Fujimoto A, Takehara K, Takata M. Hatta N, et al. Among authors: takata m. Melanoma Res. 1999 Aug;9(4):401-6. doi: 10.1097/00008390-199908000-00010. Melanoma Res. 1999. PMID: 10504060

6

Clonal heterogeneity in sporadic melanomas as revealed by loss-of-heterozygosity analysis.

Takata M, Morita R, Takehara K. Takata M, et al. Int J Cancer. 2000 Feb 15;85(4):492-7. Int J Cancer. 2000. PMID: 10699920

7

No evidence of deregulated patched-hedgehog signaling pathway in trichoblastomas and other tumors arising within nevus sebaceous.

Takata M, Tojo M, Hatta N, Ohara K, Yamada M, Takehara K. Takata M, et al. J Invest Dermatol. 2001 Dec;117(6):1666-70. doi: 10.1046/j.0022-202x.2001.01581.x. J Invest Dermatol. 2001. PMID: 11886539 Free article.

8

Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa.

Matsushita Y, Hatta N, Wakamatsu K, Takehara K, Ito S, Takata M. Matsushita Y, et al. Among authors: takata m. Melanoma Res. 2002 Aug;12(4):319-23. doi: 10.1097/00008390-200208000-00003. Melanoma Res. 2002. PMID: 12170180

9

Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma.

Hasegawa M, Takata M, Hatta N, Wakamatsu K, Ito S, Takehara K. Hasegawa M, et al. Among authors: takata m. Melanoma Res. 1997 Jun;7(3):243-51. doi: 10.1097/00008390-199706000-00009. Melanoma Res. 1997. PMID: 9195564

10

Polymerase chain reaction and immunohistochemistry frequently detect occult melanoma cells in regional lymph nodes of melanoma patients.

Hatta N, Takata M, Takehara K, Ohara K. Hatta N, et al. Among authors: takata m. J Clin Pathol. 1998 Aug;51(8):597-601. doi: 10.1136/jcp.51.8.597. J Clin Pathol. 1998. PMID: 9828818 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,232 results

Search Page

Filters